Tag: Mao b inhibitor

First approved by the FDA in 1989 for treating Parkinson's disease, selegiline's primary classification is as a monoamine oxidase inhibitor, specifically a selective and irreversible inhibitor of the MAO-B enzyme at low doses. This makes knowing **what is the medication classification of selegiline?** essential for comprehending its multifaceted clinical applications in both neurological and psychiatric contexts.

Selegiline, a monoamine oxidase inhibitor (MAOI), is effective for Parkinson's disease and depression, but its use is associated with a range of potential side effects [1.8.3]. Understanding what an adverse effect of selegiline is can help patients and caregivers manage treatment safely.

Affecting nearly 1 million people in the United States, Parkinson's disease can cause debilitating motor fluctuations known as 'off' episodes. For many with mid- to late-stage disease, safinamide is used for management as an add-on treatment to levodopa to help smooth out these symptoms.

While not the most common adverse effect, diarrhea is a reported gastrointestinal side effect of the medication selegiline, used for Parkinson's disease and other conditions. In fact, some clinical trials reported diarrhea occurring in 1-10% of patients taking oral selegiline. This article explores the connection between selegiline and diarrhea, potential causes, and management strategies.

According to a 2025 market report, the medication safinamide, marketed under the brand name Equfina in Japan and some other Asian countries, is indicated for Parkinson's disease. This targeted therapy helps manage motor fluctuations in patients already receiving treatment with levodopa/carbidopa.

First approved by the FDA in 1989 for Parkinson's disease, selegiline is a monoamine oxidase B (MAO-B) inhibitor with several important therapeutic applications. This guide delves into what is selegiline used for, its mechanism, and important considerations for patients and healthcare providers.

Affecting more than 10 million people worldwide, Parkinson's disease is a chronic and progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons. Rasalect, a brand name for rasagiline, works by specifically targeting an enzyme that breaks down dopamine, thereby increasing its availability in the brain to help control motor symptoms.